Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find
the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to
further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose
(Expansion Phase).